Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IGF2R | P11717 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550356 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL104855 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL7549080 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL284741 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL1521155 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL24021536 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL1521609 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL7549072 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL7545194 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT | |
| SCHEMBL1521156 | 1.00 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204444-A9 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204444-A9 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170016040-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170016040-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160161490-A1 | REAGENT FOR MEASURING ENDOTOXIN AND METHOD FOR MEASURING ENDOTOXIN | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-9290530-B2 | Chemoenzymatic synthesis of heparin and heparan sulfate analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290530-B2 | Chemoenzymatic synthesis of heparin and heparan sulfate analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140235575-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235575-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-21 | — | — | US | disclosed |
| US-8575131-B2 | Glucuronic acid-containing glucan, process for production of same, and use of same | NATIONAL UNIVERSITY CORPORATION KAGOSHIMA UNIVERSITY (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130004979-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120135063-A1 | GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME | EZAKI GLICO CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235575-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | HPSE, ENGASE, GALE | L3MBTL1 4655/4885IGF2R 131/4885GAA 82/4885 |
| US-20120135063-A1 | GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME | ENGASE, FUCA1, ALG8 | L3MBTL1 4214/4885IGF2R 130/4885GAA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.